Nuveen Covered Call Closed-End Funds Reveal Plans for Mergers and Update on Shareholder Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Source: Yahoo Finance
Merger Proposal: Nuveen's Boards of Trustees have approved a proposal to merge the Nuveen S&P 500 Buy-Write Income Fund (BXMX) and Nuveen Dow 30℠ Dynamic Overwrite Fund (DIAX) into the Nuveen S&P 500 Dynamic Overwrite Fund (SPXX), aiming to reduce operating expenses and increase trading volume.
Shareholder Approval: The proposed mergers are subject to shareholder approval, with annual meetings scheduled for January 29, 2026, where shareholders can also elect Board Members and submit proposals by specified deadlines.
Analyst Views on DIAX
Wall Street analysts forecast DIAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DIAX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 15.540
Low
Averages
High
Current: 15.540
Low
Averages
High
No data
About DIAX
Nuveen Dow 30SM Dynamic Overwrite Fund is a non-diversified closed-end management investment fund. The Fund's investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average (DJIA). The Fund focuses on investing approximately 80% of its assets in the thirty stocks included in the DJIA in approximately the amount such stocks are weighted in the DJIA and/or in other securities or financial instruments with economic characteristics that are similar to the thirty stocks included in the DJIA that are intended to correlate with the price movements of the DJIA. The Fund may also invest in other investment companies, including exchange-traded funds (ETFs). The Fund investments in various sectors, including software, health care providers and services, specialty retail, industrial conglomerates, information technology (IT) services and pharmaceuticals. The Fund's investment advisor is Nuveen Fund Advisors, LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
